Sagar Shah, MD
Urology · Jacksonville, FLNPI 1770604548
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by Astellas Pharma US Inc at 34.3% of the total. Reporting peaked in 2021 at $19,709 and has fallen 89.1% since, to $2,152 in 2025. Among urology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 416 payments — averaging $143.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$21K
- Axonics, Inc.$19K
- Urovant Sciences Inc$6K
- Medtronic$4K
- Contura, Inc.$3K
- Sumitomo Pharma America, Inc.$3K
- plus $5K from 38 others
Across 44 payments — averaging $2489.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$86K
- Axonics, Inc.$17K
- Boston Scientific$5K
- Astellas Pharma Global Development$1K
What the payments were for
- Consulting fees$15,82526%
- Speaking & faculty fees$27,54346%
- Travel & lodging$4,4597%
- Food & beverage$11,67120%
- Education$2830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYRBETRIQ$19,677
- Axonics r-SNM System$14,501
- GEMTESA$8,517
- Bulkamid$6,016
- Axonics$2,294
- INTERSTIM$2,242
- Desara$324
- DALVANCE$268
- Dornier MedTech$227
- Barrigel$150
- STRATAFIX$147
- DERMABOND$147
- CVAC Aspiration System$141
- BOTOX COSMETIC$136
- LithoVue$130
- REZUM$123
- OBTRYX$121
- Cook$101
How this compares
$59,781 in reported general payments places this provider in the 95th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 560 | $370,548 |
| MyrbetriqMirabegron | 523 | $330,636 |
| Solifenacin Succinate | 879 | $36,888 |
| PremarinEstrogens, Conjugated | 35 | $16,424 |
| Trospium Chloride ErTrospium Chloride | 81 | $11,550 |
| Estradiol | 174 | $11,224 |
| NitrofurantoinNitrofurantoin Macrocrystal | 249 | $5,462 |
| Fosfomycin Tromethamine | 30 | $5,078 |
| Tolterodine Tartrate ErTolterodine Tartrate | 67 | $4,046 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 29 | $2,809 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 144 | $2,282 |
| Trospium Chloride | 45 | $2,091 |
| Tamsulosin Hcl | 167 | $1,997 |
| Celecoxib | 94 | $1,672 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 274 | $1,430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $2,593 | $370,548560 claims |
| Astellas Pharma US IncMyrbetriq | $20,510 | $330,636523 claims |
| PfizerPremarin | $487 | $16,42435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 935 urology providers in Florida.
Other urology in Jacksonville
- Raymond PakJacksonville$251K
- Douglas SwartzJacksonville$118K
- Ali KasraeianJacksonville$63K
- Bryce BairdJacksonville$56K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.